Research ArticleInflammation

Treating murine inflammatory diseases with an anti-erythrocyte antibody

See allHide authors and affiliations

Science Translational Medicine  21 Aug 2019:
Vol. 11, Issue 506, eaau8217
DOI: 10.1126/scitranslmed.aau8217

Fighting inflammation with inflammation

Immune thrombocytopenia (ITP) can be treated with IVIg or even anti-D, which is immunoglobulin directed against red blood cells (RBCs). To investigate whether an anti-RBC antibody could confer benefits in other inflammatory models, Crow et al. turned to the mouse anti-RBC antibody Ter119, known to be not only inflammatory but also therapeutic in ITP models. They now show that the beneficial effects in ITP are not due to induction of anemia. Ter119 also successfully treated multiple mouse models of arthritis and prevented symptoms in an acute lung injury model. These effects were dependent on a functional Fc portion and involved modulation of monocytes and chemokines. Their results suggest that anti-RBC antibodies might be able to replace IVIg for many inflammatory indications.

View Full Text

Stay Connected to Science Translational Medicine